RW Daily. Jumped the gun. WV man sues newspaper for failing to retract story about him carjacking a man in a church parking lot. In all seriousness, it might be just an unintended ‘side effect’ of increased levels of testosteron. Peer review is a blackish box. Ultimately this can even be unrelated to the comparative testosteron levels of individuals with MPB, MPB may thus be a visual symptom of high levels of testosteron, and thus attract females, that may in turn have led to a survival advantage of those individuals that have MPB. Then, we must open it up. Threaded commenting powered by interconnect/it code. Since it was a bit different from the sorts of journal retractions we usually cover, we asked Retraction Watch friend and TheStreet.com biotech columnist Adam Feuerstein to interpret this for us.
Regulators started asking questions about plenty of the claims being made, or at a minimum, the company was worried that regulators will come a’calling, So in case I had to guess.
Replicel is now publicly disavowing the work of the stock promoters they hired, with the intention to wiggle out of the real problem. It appears the company hired pennystock promoters to publicize or pump the company but these promoters went a bit overboard with their claims. Are reproducibility and open science starting to matter in tenure and promotion review? Of course, we need to achieve a world where universities can have no confidence that reports will remain buried. Just after an investigation uncovered a case of serious misconduct that included manipulation of data, the Weizmann Institute in Israel has barred a biologist from mentoring graduate students. In. Albeit the Company notes such certain disclosures were not authorized by the Company, the Company wishes to make a general retraction in respect of certain disclosures. Talking about chemical probes,. Nonetheless, I wanted to pass on that is filed on Sedar.
Even if it does work as expected, price targets and dramatic increases in share costs indicated in such publications may never be met and there’re many risks and uncertainties pertaining to the Company’s business and shares that may cause investors to lose their entire investment in the Company, including that the Company’s technology may not work as expected and, the Company might be unable to successfully commercialize the technology or protect its intellectual property from competitors.
Specifically, the Company wishes to make clear that, given the Company’s current stage of development, price targets and estimates pertaining to expected increases in the Company’s share price, as published in the aforementioned reports are premature and can not be relied upon.
Release from ‘Vancouverbased’ Replicel, that takes dermal sheath cup cells…from a subject’s own healthy hair follicles, replicates them into the millions over a three month period, and reintroduces them into areas of hair loss with the anticipated result the development of new hair follicles. VANCOUVER, BC -April 27, 2012 -RepliCel Life Sciences Inc. Lake Group Media Inc. Some info can be found on the web. NBT Equities Research/NBT Communications were hired by the Company to build awareness.
Disclosures were published in reports available online or delivered via email newsletter, including TheHotPennyStocks.com.com, StockGuru and in other disclosures published by Lake Group Media Inc, and in an equity research report published by NBT Equities Research/NBT Communications which contained certain price targets and a strong buy recommendation.
In a hunter gatherer tribe, where females synchronize their menstruation with the full moon, the males know exceedingly well when they must organize a hunt.
Followers in the hunt can see their leader most clearly, even from a distance, with the full moon reflecting on his hairless head.
On this outing, the wisest man leads.
Survival Advantage of Baldness.
Baldness in women, ofcourse, does not convey a similar ‘legup’. Tribe thus has an evolutionary advantage. If a release put out a couple of days later is any indication, the retraction may have little do with the company’s actual results. Company is delighted to report that the ‘six month’ interim analysis results support the continued development of DSCC for the treatment of androgenetic alopecia. Results of this first in man trial tell us that we are on the right track in developing an effective treatment for people suffering from pattern baldness. This is where it starts getting serious, right? The assessment of the primary endpoint of the TS001 2009 clinical trial shows a favourable local safety profile for injections of autologous hair follicle cells, said Darrell Panich, RepliCel’s VicePresident of Clinical Affairs. We are also encouraged that the early analysis of efficacy endpoints has shown a trend for improvement in hair growth parameters and a statistically significant number of participants showing a treatment response. Remember, a quick look at MPB forums will tell you how desperate a certain amount these poor guys are, the majority of whom are very young, that is a time when hair loss can be very difficult to deal with.